公开(公告)号：US20230287120A1

公开(公告)日：2023-09-14

申请号：US18308143

申请日：2023-04-27

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Yi ZHANG ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Silvia K. TACHEVA-GRIGOROVA ,  Barbra Johnson SASU

IPC: C07K16/28 ,  A61P35/00 ,  C12N15/63

CPC classification number: C07K16/2809 ,  A61P35/00 ,  C07K16/2887 ,  C12N15/63 ,  A61K2039/505

Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.

公开(公告)号：US20210107979A1

公开(公告)日：2021-04-15

申请号：US16802822

申请日：2020-02-27

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Yi ZHANG ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Silvia K. TACHEVA-GRIGOROVA ,  Barbra Johnson SASU

IPC: C07K16/28 ,  C12N15/63 ,  A61P35/00

Abstract: Provided herein are DLL3 binding agents and chimeric antigen receptors (CARs) comprising a DLL3 binding molecule that specifically binds to DLL3; and immune cells comprising these DLL3-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using DLL3-specific CARs, and immune cells comprising DLL3-specific CARs.

公开(公告)号：US20220227832A1

公开(公告)日：2022-07-21

申请号：US17557654

申请日：2021-12-21

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Shanshan LANG ,  Thomas John VAN BLARCOM ,  Michael Thomas BETHUNE ,  Siler PANOWSKI ,  Nguyen TAN ,  Yi ZHANG ,  Barbra Johnson SASU ,  Zhe LI

IPC: C07K14/725 ,  C07K14/705 ,  C12N15/79 ,  C07K19/00

Abstract: A reversibly gated effector polypeptide e.g. a chimeric antigen receptor (protease-activating CD45-gate CAR) comprising an extracellular CD45 recruiting domain, a protease-cleavable linker, and a polypeptide comprising an extracellular ligand binding domain, a transmembrane domain, and an intracellular domain. Nucleic acids including vectors and expression vectors that encode the protease-activating CD45-gate CAR and cells including immune cells such as T cells that comprise and express the nucleic acids. Methods of treatment of various conditions including various forms of cancer comprising administering the cells including CAR T cell therapy. In some embodiments, the CD45 gate at least partially inhibits activation of the protease-activating CD45-gate CAR when the protease-activating CD45-gate CAR binds antigen. The inhibition is at least partially diminished, relieved and/or eliminated when the protease-activating CD45-gate CAR is exposed to a protease that can cleave the linker.

公开(公告)号：US20240216430A1

公开(公告)日：2024-07-04

申请号：US18521196

申请日：2023-11-28

Applicant: ALLOGENE THERAPEUTICS, INC. ,  PFIZER INC.

Inventor： Zhe LI ,  Siler PANOWSKI ,  Barbra Johnson SASU ,  Bryan A. SMITH ,  Thomas John VAN BLARCOM ,  Tao SAI ,  Guoyun ZHU

IPC: A61K35/17 ,  A61K39/00 ,  C07K16/28

CPC classification number: A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464438 ,  C07K16/2875 ,  A61K2039/505 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/23 ,  A61K2239/29 ,  A61K2239/31 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622

Abstract: Provided herein are Claudin 18.2 binding agents and chimeric antigen receptors (CARs) comprising a Claudin 18.2 binding molecule that specifically binds to Claudin 18.2; and immune cells comprising these Claudin 18.2-specific CARs, e.g., CAR-T cells. Also provided are methods of making and using Claudin 18.2-specific CARs and Claudin 18.2 binding agents, and immune cells comprising Claudin 18.2-specific CARs.

公开(公告)号：US20220023346A1

公开(公告)日：2022-01-27

申请号：US17381693

申请日：2021-07-21

Applicant: Allogene Therapeutics, Inc.

Inventor： Michael Thomas BETHUNE ,  Yi ZHANG ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Barbra Johnson SASU

IPC: A61K35/17 ,  C12N15/86 ,  C07K14/725 ,  C12N5/0783

Abstract: Provided herein are recombinant antigen receptors, for example chimeric antigen receptors (CARs), that comprise modified cytoplasmic domains that provide improved signalling and thereby provide improved performance and safety. Also provided are polynucleotides encoding the recombinant antigen receptors, vectors comprising the polynucleotides, and engineered immune cells comprising the vectors and/or polynucleotides. The invention further provides methods for engineering immune cells to express the recombinant antigen receptors. Improved recombinant antigen receptor signalling is also provided by co-expressing a first recombinant antigen receptor and a second recombinant antigen receptor or co-expressing a recombinant antigen receptor and a protein involved in transducing the signal from the activated recombinant antigen receptor. Also provided are methods of treating a variety of conditions, including, but not limited to, blood cancers and cancers characterized by solid tumors, by administering the engineered cells to patients suffering from such a condition.

公开(公告)号：US20200339944A1

公开(公告)日：2020-10-29

申请号：US16857394

申请日：2020-04-24

Applicant: ALLOGENE THERAPEUTICS, INC.

Inventor： Diego A. VARGAS-INCHAUSTEGUI ,  Thomas Charles PERTEL ,  Barbra Johnson SASU

IPC: C12N5/00 ,  C12N5/0783 ,  A61K35/17

Abstract: Described herein are improved media for culturing immune cells, and methods of use thereof. In particular, cell growth media described herein are particularly suitable for T-cell expansion, which can be used for manufacture of cells useful in adoptive cell therapies, including therapies using chimeric antigen receptors (e.g., CAR-T cell therapy).

公开(公告)号：US20200276238A1

公开(公告)日：2020-09-03

申请号：US16804545

申请日：2020-02-28

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui LIN ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Barbra Johnson SASU

IPC: A61K35/17 ,  C07K14/715 ,  C07K16/28 ,  C12N15/67 ,  C07K16/30

Abstract: Provided herein are PD-1 chimeric cytokine receptors. When present on chimeric antigen receptor (CAR)-bearing immune cells, such receptors allow for increased immune cell activation, proliferation, persistence, and/or potency, when engaged with PD-1 ligands or activation with an anti-PD-1 antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.

公开(公告)号：US20240360196A1

公开(公告)日：2024-10-31

申请号：US18607387

申请日：2024-03-15

Applicant: ALLOGENE THERAPEUTICS, INC. ,  CELLECTIS

Inventor： Arvind RAJPAL ,  Shobha Chowdary POTLURI ,  Laurent POIROT ,  Alexandre JUILLERAT ,  Thomas Charles PERTEL ,  Donna Marie STONE ,  Barbra Johnson SASU

IPC: C07K14/705 ,  A61K35/17 ,  A61K39/00 ,  C07K14/725 ,  C07K16/28 ,  C07K16/30 ,  C12N5/0783

CPC classification number: C07K14/70503 ,  A61K35/17 ,  C07K14/7051 ,  C07K14/70517 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/2803 ,  C07K16/3069 ,  C12N5/0636 ,  A61K2039/5156 ,  C07K2317/622 ,  C07K2317/76 ,  C07K2319/03 ,  C07K2319/70 ,  C07K2319/74 ,  C12N2510/00

Abstract: The invention relates to an inhibitory chimeric antigen receptor (N-CAR) comprising



an extracellular domain comprising an antigen binding domain,
a transmembrane domain and,
an intracellular domain
wherein the intracellular domain comprises an Immunoreceptor Tyrosine-based Switch Motif ITSM, wherein said ITSM is a sequence of amino acid TX1YX2X3X4, wherein
X1 is an amino acid
X2 is an amino acid
X3 is an amino acid and
X4 is V or I.

公开(公告)号：US20220409665A1

公开(公告)日：2022-12-29

申请号：US17841041

申请日：2022-06-15

Applicant: Allogene Therapeutics, Inc.

Inventor： Elvin J. LAURON ,  Siler PANOWSKI ,  Barbra Johnson SASU ,  Cesar Adolfo SOMMER ,  Surabhi SRIVATSA SRINIVASAN ,  Thomas John VAN BLARCOM ,  Shanshan LANG

IPC: A61K35/17 ,  C07K16/28 ,  A61P35/00

Abstract: Provided herein are CD70-binding proteins comprising a CD70-binding domain and a transmembrane domain, engineered immune cells comprising the CD70-binding proteins, and methods of making and using the same. Also provided herein are engineered immune cells e.g. CAR (chimeric antigen receptor) T cells for administration to patients to treat cancer (e.g., solid tumors and hematologic tumors) and other unwanted conditions. The cells are engineered to functionally express a first antigen binding molecule e.g. a CD70 CAR and a second antigen binding molecule e.g. a second CAR that binds a target molecule characteristic of the cancer or other disease or unwanted condition. The cells may be further engineered to reduce the functional expression level of one or more of TRAC, CD52 and CD70. Also provided are methods of making and using the engineered cells, compositions and kits comprising them, and methods of treating by administering them.

公开(公告)号：US20240016846A1

公开(公告)日：2024-01-18

申请号：US18365014

申请日：2023-08-03

Applicant: Allogene Therapeutics, Inc.

Inventor： Regina Junhui LIN ,  Thomas John VAN BLARCOM ,  Siler PANOWSKI ,  Barbra Johnson SASU

IPC: A61K35/17 ,  C07K14/715 ,  C07K16/28 ,  C07K16/30 ,  C12N15/67

CPC classification number: A61K35/17 ,  C07K14/7155 ,  C07K16/2818 ,  C07K16/30 ,  C12N15/67 ,  A61K38/00

Abstract: Provided herein are PD-1 chimeric cytokine receptors. When present on chimeric antigen receptor (CAR)-bearing immune cells, such receptors allow for increased immune cell activation, proliferation, persistence, and/or potency, when engaged with PD-1 ligands or activation with an anti-PD-1 antibody. Also provided are methods of making and using the chimeric cytokine receptors described herein.